BIRC7
Overview
BIRC7 (baculoviral IAP repeat containing 7, also known as ML-IAP/livin) is an inhibitor of apoptosis protein. It is overexpressed in tumors with MiTF family fusion or amplification events in non-clear-cell renal cell carcinoma, where it has been proposed as both a diagnostic biomarker and therapeutic target.
Alterations observed in the corpus
- Overexpressed in 6/7 MiTF-fusion/amplification (MiTF-high) samples in nccRCC; proposed as a therapeutic target via BIRC7 inhibitors/apoptosis-sensitizing agents PMID:25401301
Cancer types (linked)
- PRCC / TRCC: BIRC7 overexpression marks the MiTF-high subtype (ACTG1-MITF, TFE3, TFEB fusions/amplifications) across pRCC and tRCC subtypes PMID:25401301
Co-occurrence and mutual exclusivity
- Co-expressed with MITF, TFE3, and TFEB fusion/amplification events; mechanistically downstream of MiTF transcriptional activation PMID:25401301
Therapeutic relevance
- BIRC7 expression proposed as a diagnostic biomarker for MiTF-high tumors and as a therapeutic target via BIRC7-directed apoptosis-sensitizing agents in clinical development PMID:25401301
Open questions
- Whether BIRC7 inhibition is selectively lethal in MiTF-high tumors (vs normal kidney) and whether it can be combined with MET inhibitors awaits clinical testing PMID:25401301
Sources
This page was processed by entity-page-writer on 2026-05-11.